Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors. Andricovich J, Lap CJ, Tzatsos A. Blood 2025;146:1493-1510.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Andricovich J, Lap CJ, Tzatsos A. Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors. Blood 2025;146:1493-1510.
PMID: 40540751